Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodohippurate sodium I-123 is a radiopharmaceutical diagnostic agent used primarily to evaluate effective renal plasma flow (ERPF) and kidney function. It consists of o-iodohippuric acid labeled with the radioactive isotope iodine-123. After intravenous administration, it is rapidly cleared from the bloodstream by the kidneys and excreted in urine, allowing for dynamic imaging of renal perfusion and function using gamma cameras or SPECT. The mechanism of action involves filtration and tubular secretion by the kidneys; its pharmacokinetics make it suitable for quantitative assessment of renal plasma flow. It is not used therapeutically but as a diagnostic tool in nuclear medicine[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iodohippurate sodium I-123.